wildtype CD19 CAR T cells

Wildtype CD19 CAR T cells are T cells genetically engineered to express a chimeric antigen receptor (CAR) targeting the CD19 protein, without additional genetic modifications to regulatory genes such as LRIG1. In clinical practice, CD19-directed CAR T cell therapies (e.g., tisagenlecleucel, axicabtagene ciloleucel) are used to treat various B-cell malignancies, including B-cell lymphomas and leukemias. In research contexts, "wildtype" CAR T cells serve as the standard control to evaluate the efficacy of next-generation modifications, such as gene knockouts or metabolic enhancements, intended to improve persistence and overcome exhaustion in the tumor microenvironment. The provided research context highlights that wildtype CAR T cells exhibit antigen-density dependent upregulation of LRIG1, which acts as an inhibitory receptor for VISTA, thereby limiting their functional capacity compared to LRIG1-deficient versions.

Other names

WT CD19 CAR-Tstandard CD19 CAR-TWT CART